<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655731</url>
  </required_header>
  <id_info>
    <org_study_id>FF117/2015</org_study_id>
    <nct_id>NCT02655731</nct_id>
  </id_info>
  <brief_title>HeartLight Guided - Pure Pulmonary Vein Isolation Regardless of Concomitant Atrial Substrate</brief_title>
  <acronym>HEURECA</acronym>
  <official_title>HeartLight Guided - Pure Pulmonary Vein Isolation Regardless of Concomitant Atrial Substrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardioangiologisches Centrum Bethanien</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardioangiologisches Centrum Bethanien</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the present prospective, single-centre study is to determine the outcome after pure
      PVI using HeartLight™ in 100 patients with different extents of LA-LVA.

      The latter will be assessed by an electro-anatomical voltage map using a commercial 3D
      mapping system (CARTO, Biosense Webster).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ablation strategy for patients with atrial fibrillation (AF) and concomitant atrial
      substrate (e.g. low-voltage areas; LVA) is a matter of controversy.

      Results of studies investigating the impact of LVA may have been confounded by
      PV-to-left-atrial (LA) reconnection due to non-durable ablation. Therefore, the true
      contribution of LA-LVA to AF recurrences remains unknown.

      Meanwhile, new ablation technologies such as the HeartLight™ laser balloon (LB) ablation
      system providing near complete chronic PVI rates have been developed.

      Aim of the present prospective, single-centre study is to determine the outcome after pure
      PVI using HeartLight™ in 100 patients with different extents of LA-LVA.

      The latter will be assessed by an electro-anatomical voltage map using a commercial 3D
      mapping system (CARTO, Biosense Webster).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from atrial fibrillation and atrial tachyarrhythmias</measure>
    <time_frame>12 months</time_frame>
    <description>72h Holter-ECG recordings will be performed. In case of clinical arrhythmia symptoms event-recording will be provided.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PVI with HeartLight</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PVI with HeartLight</intervention_name>
    <description>Catheter ablation</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic atrial fibrillation

          -  Left atrial size &lt;50mm

          -  Left ventricular ejection fraction &lt;45%

          -  Patient is able to provide informed consent

        Exclusion Criteria:

          -  Contraindications for PVI

          -  Previous PVI attempts

          -  Inability to be treated with oral anticoagulation

          -  Presence of intracardiac thrombi

          -  Pregnancy

          -  Participation in other clinical studies

          -  Unwilling to follow the study protocol and to attend follow-up visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris Schmidt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardioangiologisches Centrum Bethanien</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardioangiologisches Centrum Bethanien</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardioangiologisches Centrum Bethanien</investigator_affiliation>
    <investigator_full_name>Boris Schmidt</investigator_full_name>
    <investigator_title>Head of Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

